Laddar...
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Abstract Background Omalizumab is licensed as add-on therapy for patients with severe allergic asthma. Response is in most studies scored by the physician’s global evaluation of treatment effectiveness (GETE). A good clinical and validated parameter for treatment response is currently missing. Also,...
Sparad:
| Huvudupphovsmän: | , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
BMC
2017-07-01
|
| Serie: | Allergy, Asthma & Clinical Immunology |
| Ämnen: | |
| Länkar: | http://link.springer.com/article/10.1186/s13223-017-0206-9 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|